Press Releases

 
Press Releases
  Date Title View
Sep 21, 2017
RADNOR, Pa., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated...
Sep 19, 2017
RADNOR, Pa., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the closing of an underwritten public offering of 10,733,334 shares of its common stock for a public offering price of $3.75 per share. This includes the exercise in full by the underwriter of i...
Sep 15, 2017
RADNOR, Pa., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the pricing of an underwritten public offering of 9,333,334 shares of common stock for a public offering price of $3.75 per share. The gross proceeds from the offering are expected to be $35 milli...
Sep 14, 2017
RADNOR, Pa., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  The offering is subject to market conditions, and there can be no assurance as to whether or...
Sep 11, 2017
Substantial and Durable Anti-Seizure Efficacy Shown in Patients Suffering From Severe,  Rare Genetic Epilepsy Marinus to Host Conference Call and Webcast Today at 9:00 am EDT RADNOR, Pa., Sept. 11, 2017 (GLOBE NEWSWIRE) --  ...
Aug 1, 2017
Data from Studies in Rare Pediatric Epilepsies and Severe Postpartum Depression Expected in 2nd Half On-track to Initiate Two Additional Phase 2 Trials Later This Year in Status Epilepticus and Moderate Postpartum Depression RADNOR, Pa., Aug. 0...
Jun 29, 2017
RADNOR, Pa., June 29, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicate...
Jun 27, 2017
Program to Evaluate Intravenous and Oral Ganaxolone in Patients with Severe or Moderate Postpartum Depression RADNOR, Pa., June 27, 2017 (GLOBE NEWSWIRE) -- ...
May 1, 2017
RADNOR, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical com...
Apr 18, 2017
Platform Presentation of Phase 2 Data in Fragile X Syndrome RADNOR, Pa., April 18, 2017 (GLOBE NEWSWIRE) -- ...
1
...
NextLast
= add release to Briefcase